

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA - Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation a potential equalities issue was raised. Current practice allows for treatment of patients with homozygous F508 genetic mutations to use modulator therapies and the triple therapy may also be used in the heterozygous F508 genetic mutations. Issues related to differences in prevalence or incidence of a disease or genetic mutation cannot be addressed in a technology appraisal.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The potential equality issue identified was considered a function of the clinical condition and not the technology under assessment and therefore is not considered an equalities issue.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made to the draft scope.

Technology Appraisals: Scoping

Equality impact assessment for the proposed Single Technology Appraisal of Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation

Issue date: February 2020

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders identified.

Approved by Associate Director (name): Linda Landells

Date: 18 February 2020